NasdaqGS:HON
NasdaqGS:HONIndustrials

Has Honeywell’s Recent Share Price Slide Created a Long Term Opportunity in 2025?

Wondering if Honeywell International is starting to look like a bargain, or if the recent dip is just a value trap in disguise? This breakdown will help you decide with a clear, valuation-first lens. The stock is trading around $190.17 after sliding about 1.5% over the last week and roughly 2.0% over the past month, adding to a year-to-date decline of about 15.7% and a 10.0% drop over the last year. Those softer returns come as investors reassess industrial names amid shifting interest rate...
NYSE:STEL
NYSE:STELBanks

Taking Stock of Stellar Bancorp (STEL)’s Valuation After Its Recent Share Price Strength

Stellar Bancorp Stock Overview Stellar Bancorp (STEL) has quietly outperformed many regional peers this year, with the stock up about 14% year to date and roughly 5% over the past month, drawing fresh investor attention. See our latest analysis for Stellar Bancorp. With the share price now at $31.74 and a 30 day share price return of 5.41%, momentum looks to be building on top of a solid year to date gain and respectable multi year total shareholder returns. If you want to see how other...
NYSE:LMT
NYSE:LMTAerospace & Defense

Is It Time to Reassess Lockheed Martin’s Valuation After Recent Defense Contract Wins?

Many investors are asking whether Lockheed Martin is still attractive at around $465 a share, or if most of the potential upside has already been reflected in the price. This breakdown examines that question in detail. The stock has risen about 6% over the last week and 1.5% over the past month, but it is still down 3.5% year to date and roughly 6.1% over the last year. In that context, its 49.3% gain over five years may appear somewhat underappreciated. Recent headlines have highlighted...
NYSE:IONQ
NYSE:IONQTech

IonQ (IONQ) Valuation Check After Slovakia Quantum Network Launch and New Regenerative Medicine Partnership

IonQ (IONQ) just checked two big boxes at once, rolling out Slovakia’s first national quantum communication network while also teaming up with a leading regenerative medicine group on quantum AI powered drug development. See our latest analysis for IonQ. All of this comes as IonQ’s share price has climbed to about $54.36, with a 7 day share price return of 15.37% and a 1 year total shareholder return of 58.76%. This suggests momentum is rebuilding after recent volatility and is still grounded...
NYSE:CAL
NYSE:CALSpecialty Retail

Caleres (CAL) Q3 2026 Margin Collapse Reinforces Bearish Profitability Narratives

Caleres (CAL) opened Q3 2026 with total revenue of about $790 million and EPS of $0.07, while trailing twelve month revenue stood at roughly $2.7 billion with EPS of $0.52, setting a cautious tone around profitability. The company has seen revenue move from $741 million and EPS of $1.20 in Q3 2025 to $790 million and EPS of $0.07 in Q3 2026, a shift that leaves investors watching how much of the story is about topline resilience versus pressure further down the income statement. With net...
NasdaqGM:APGE
NasdaqGM:APGEBiotechs

Apogee Therapeutics (APGE) Is Up 10.3% After Strong APG333 Phase 1 Data And $345M Raise – What's Changed

In recent days, Apogee Therapeutics reported positive interim Phase 1 results for its lead antibody APG333, showing a roughly 55-day half-life and biomarker suppression lasting up to six months, while also closing a public offering that raised about US$345,000,000 in gross proceeds. These updates, reinforced by multiple optimistic analyst views and insider stock sales executed under pre-arranged Rule 10b5-1 plans, spotlight a company pairing a potentially convenient dosing profile with a...
NYSE:DBI
NYSE:DBISpecialty Retail

Designer Brands (DBI) Q3 2026 Profit Rebound Tests Bearish Loss-and-Coverage Narrative

Designer Brands (DBI) has just posted its Q3 2026 numbers, logging revenue of $752 million and basic EPS of $0.35 as net income reached $18.2 million. The company has seen revenue move from $771.9 million in Q2 2025 to $777.2 million in Q3 2025 and then to $752 million in the latest quarter, while EPS has swung from $0.24 in Q2 2025 to $0.25 in Q3 2025 and now $0.35. This sets up a narrative where higher profitability in the latest quarter sits against a still choppy top line. Overall,...
NasdaqGS:CHTR
NasdaqGS:CHTRMedia

Is Charter Communications a Rare Bargain After a 44% Share Price Slide?

Wondering if Charter Communications at around $204 a share is a value trap or a rare bargain hiding in plain sight? You are not the only one looking at this beaten up cable giant and asking if the downside has already been priced in. Despite a rough longer term track record, with the stock down about 41.4% year to date and 44.1% over the last year, it has shown some short term life, gaining roughly 3.9% in the last week after a 6.9% slide over the past month. Recent moves have been driven...
NYSE:CTRA
NYSE:CTRAOil and Gas

Is Coterra Energy Attractively Priced After Strong Cash Returns and 5 Year 100% Gain?

If you are wondering whether Coterra Energy is still a smart buy at around $26.86, you are not alone, and the numbers behind its valuation are more interesting than the headline price suggests. The stock has inched up 1.8% over the last week and 1.1% over the last month, and those modest near term moves sit on top of a 12.1% 1 year gain and a 100.9% rise over 5 years. Recent news flow around disciplined capital allocation, including continued focus on returning cash to shareholders through...
NasdaqGS:MANH
NasdaqGS:MANHSoftware

Manhattan Associates (MANH): Valuation Check After 41% Pullback From Peak

Manhattan Associates (MANH) has quietly slid over the past year, with the stock down about 41% from its peak even as revenue and net income keep growing at a steady, mid single digit clip. See our latest analysis for Manhattan Associates. That slide has been driven less by a single headline and more by a reset in expectations, with a roughly 16.7% 90 day share price decline and a far steeper 40.6% one year total shareholder return drop contrasting with still healthy multi year total...
NYSE:CUZ
NYSE:CUZOffice REITs

Should Zacks Rank Upgrade And Rising Estimates Require Action From Cousins Properties (CUZ) Investors?

Cousins Properties recently received an upgrade to a Zacks Rank #2 (Buy), after analysts steadily raised their earnings estimates over recent months. This shift in analyst sentiment points to improving expectations for the REIT’s underlying business performance and earnings outlook. Next, we’ll explore how the Zacks rating upgrade and rising earnings estimates may reshape Cousins Properties’ broader investment narrative. Outshine the giants: these 27 early-stage AI stocks could fund your...
NasdaqGM:BLBD
NasdaqGM:BLBDMachinery

Assessing Blue Bird’s (BLBD) Valuation After a Strong Q4 Beat, Analyst Upgrades and Insider Buying

Fourth Quarter Beat and Insider Buying Put Blue Bird in Focus Blue Bird (BLBD) just delivered a stronger than expected fiscal fourth quarter, with earnings and revenue topping forecasts, followed quickly by an insider share purchase that underscores management’s confidence. See our latest analysis for Blue Bird. The upbeat quarter and insider buying come after a choppy few months, with a roughly flat 1 month share price return. However, the year to date share price return of about 31 percent...
NYSE:TXT
NYSE:TXTAerospace & Defense

Is Textron Still Attractively Priced After Strong Multi Year Share Price Gains?

Wondering whether Textron is still a smart buy at today’s price, or if most of the upside is already baked in? This breakdown will help you decide with a cool head. The stock has quietly climbed 1.8% over the last week and 2.3% over the past month, adding to a 10.7% gain year to date and a strong 75.5% over five years, which naturally raises the question of how much value is left on the table. Recent news has focused on Textron’s growing defense and aviation footprint, from expanding...
NYSE:CVS
NYSE:CVSHealthcare

Is CVS Health Still Attractive After Its 2025 Rally and Cash Flow Outlook?

If you are wondering whether CVS Health is still a bargain after its big comeback, you are not alone. This stock has quietly turned into one of the more interesting value stories in healthcare. After a choppy few years, CVS is up 76.9% year to date and 47.9% over the last 12 months, even though the last month was slightly negative at -0.9% and the last week only inched ahead by 0.8%. Part of this renewed interest comes from CVS leaning harder into its integrated healthcare model, combining...
NasdaqGS:FFIV
NasdaqGS:FFIVCommunications

Is It Too Late To Consider F5 After Its Recent Share Price Surge?

If you are wondering whether F5 at around $257 a share is still worth considering after its big run, or if you have missed the boat, this is a good place to unpack what the current price implies. Over the last week the stock is up 8.2%, adding to a 5.0% gain over 30 days and a 66.9% rise over three years, even though the 1 year return is only 0.9% and the move year to date is 2.5%. That uneven performance has played out alongside a steady sequence of product and strategy updates, from F5...
NYSE:LUMN
NYSE:LUMNTelecom

Lumen Technologies (LUMN) Valuation Check After New AWS Security Launch and Leadership Transition

Lumen Technologies (LUMN) just gave investors a lot to digest, pairing a fresh cybersecurity launch for AWS customers with a pending handoff in its top technology role. Both moves point straight at its cloud security ambitions. See our latest analysis for Lumen Technologies. The leadership shuffle and new AWS security product land as Lumen’s share price sits at $8.37, with a punchy 90 day share price return of 48.67 percent and a 3 year total shareholder return of 50.54 percent, suggesting...
NasdaqGS:FLEX
NasdaqGS:FLEXElectronic

Has Flex’s 301% Three Year Surge Left Its Shares Priced For Perfection In 2025?

If you are wondering whether Flex is still attractive after such a huge run, or if you may be late to the party, this breakdown will help you assess whether the current price still makes sense. The stock has surged 17.6% over the last week, is up 7.8% in the past month, and has risen 74.9% year to date, with a 78.1% gain over the last year and 301.1% over three years, which has clearly changed how the market views its potential. Recently, investors have been reacting to Flex’s role in...
NYSE:SNOW
NYSE:SNOWIT

Is Snowflake’s Recent Pullback Creating a Fresh Opportunity in 2025?

Wondering if Snowflake is still worth buying after its run up and recent wobble, or if the smart money has already moved on? You are not alone, and that is exactly what we are going to unpack here. Despite a strong longer term picture with the stock up 43.0% year to date and 31.3% over the last year, the recent pullback of 13.2% over 7 days and 14.3% over 30 days has reset expectations and opened up fresh questions about risk and reward. Those swings have come as investors digest a wave of...
NYSE:WM
NYSE:WMCommercial Services

Waste Management (WM) Valuation Check After Recent Share Price Pullback

Waste Management (WM) has quietly outperformed many defensive names this year, and with the stock recently pulling back from its highs, investors are asking whether this is a healthy pause or an early warning sign. See our latest analysis for Waste Management. At around $209.31 per share, WM has given investors a modest 4.37 percent year to date share price return. A 93.91 percent total shareholder return over five years suggests the recent pullback looks more like cooling momentum than a...
NasdaqGS:PGNY
NasdaqGS:PGNYHealthcare

Progyny (PGNY): Revisiting Valuation After a 10% Monthly Rally and 57% One-Year Share Price Surge

Progyny (PGNY) has quietly climbed about 10% over the past month and roughly 57% over the past year, prompting a closer look at what is driving sentiment around this fertility benefits specialist. See our latest analysis for Progyny. That recent 10.4% 1 month share price return, on top of a strong year to date share price gain, suggests momentum is rebuilding as investors refocus on Progyny’s growth and reassess past worries reflected in its weaker multi year total shareholder returns. If...
NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Is Biogen’s Recent 20% Rally Just the Start as Valuation Signals Turn Attractive?

Wondering if Biogen is quietly becoming a bargain again, or if the market still has it priced like yesterday's story? This breakdown will walk you through what the numbers are really saying about its value. After a tough few years, the stock has started to show signs of life, with shares up around 1.5% over the last week, 16.0% over the past month, and 20.3% year to date, even though the 3-year and 5-year returns remain negative. Recent moves have been driven by shifting sentiment around...
NYSE:PRMB
NYSE:PRMBBeverage

Weighing Primo Brands Valuation After 9.1% Rebound and Strategic Refocus in 2025

If you are wondering whether Primo Brands at around $15.77 is a bargain or a value trap, you are not alone. This stock has all the ingredients of a classic valuation puzzle. Over the last month the share price has climbed roughly 9.1%, even though it is still down 49.1% year to date and 47.7% over the last year. This suggests that sentiment is shifting, but the long-term scars are still visible. That recent rebound has come as investors digested a series of strategic updates, including...
NasdaqGS:COST
NasdaqGS:COSTConsumer Retailing

Does Costco Still Justify Its Premium Price After Recent Share Price Slip?

If you have ever wondered whether Costco Wholesale is still a smart buy at around $887 a share, you are not alone. Plenty of investors are trying to figure out if the current price still leaves room for value. The stock has slipped recently, down about 2.7% over the last week, 3.8% over the past month, and 2.5% year to date, yet it still sits on gains of 89.6% over 3 years and 150.5% over 5 years, which keeps the long term story in focus. Much of the recent share price action has been driven...
NYSE:CCK
NYSE:CCKPackaging

Has the Recent Pullback Created a Fresh Opportunity in Crown Holdings Stock?

Wondering if Crown Holdings is actually good value at around $94 a share, or if the easy money has already been made, you are not alone. Despite being up 16.0% year to date and 8.5% over the last year, the stock has cooled recently with a 4.0% dip over the past week and a 3.7% slide across the last month. Those moves have come as investors reassess packaging stocks more broadly, with Crown often in the conversation thanks to its global footprint and exposure to consumer staples. At the same...